179 related articles for article (PubMed ID: 29975048)
1. Identification of a PDE4-Specific Pocket for the Design of Selective Inhibitors.
Feng X; Wang H; Ye M; Xu XT; Xu Y; Yang W; Zhang HT; Song G; Ke H
Biochemistry; 2018 Jul; 57(30):4518-4525. PubMed ID: 29975048
[TBL] [Abstract][Full Text] [Related]
2. Action of a Novel PDE4 inhibitor ZL-n-91 on lipopolysaccharide-induced acute lung injury.
Tang HF; Lu JJ; Tang JF; Zheng X; Liang YQ; Wang XF; Wang YJ; Mao LG; Chen JQ
Int Immunopharmacol; 2010 Apr; 10(4):406-11. PubMed ID: 20074667
[TBL] [Abstract][Full Text] [Related]
3. Exploring the Role of Water Molecules in the Ligand Binding Domain of PDE4B and PDE4D: Virtual Screening Based Molecular Docking of Some Active Scaffolds.
Singh P; Mishra M; Agarwal S; Sau S; Iyer AK; Kashaw SK
Curr Comput Aided Drug Des; 2019; 15(4):334-366. PubMed ID: 30394213
[TBL] [Abstract][Full Text] [Related]
4. Three-dimensional structures of PDE4D in complex with roliprams and implication on inhibitor selectivity.
Huai Q; Wang H; Sun Y; Kim HY; Liu Y; Ke H
Structure; 2003 Jul; 11(7):865-73. PubMed ID: 12842049
[TBL] [Abstract][Full Text] [Related]
5. Catecholic amides as potential selective phosphodiesterase 4D inhibitors: Design, synthesis, pharmacological evaluation and structure-activity relationships.
Zhou ZZ; Ge BC; Chen YF; Shi XD; Yang XM; Xu JP
Bioorg Med Chem; 2015 Nov; 23(22):7332-9. PubMed ID: 26526739
[TBL] [Abstract][Full Text] [Related]
6. Thiophene inhibitors of PDE4: crystal structures show a second binding mode at the catalytic domain of PDE4D2.
Nankervis JL; Feil SC; Hancock NC; Zheng Z; Ng HL; Morton CJ; Holien JK; Ho PW; Frazzetto MM; Jennings IG; Manallack DT; Martin TJ; Thompson PE; Parker MW
Bioorg Med Chem Lett; 2011 Dec; 21(23):7089-93. PubMed ID: 22030030
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological and molecular dynamics analyses of differences in inhibitor binding to human and nematode PDE4: Implications for management of parasitic nematodes.
Schuster KD; Mohammadi M; Cahill KB; Matte SL; Maillet AD; Vashisth H; Cote RH
PLoS One; 2019; 14(3):e0214554. PubMed ID: 30917179
[TBL] [Abstract][Full Text] [Related]
8. Diastereoselective synthesis and profiling of bicyclic imidazolidinone derivatives bearing a difluoromethylated catechol unit as potent phosphodiesterase 4 inhibitors.
Dorokhov VS; Golovanov IS; Tartakovsky VA; Sukhorukov AY; Ioffe SL
Org Biomol Chem; 2018 Oct; 16(38):6900-6908. PubMed ID: 30024008
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and bioactivity of phenyl substituted furan and oxazole carboxylic acid derivatives as potential PDE4 inhibitors.
Lin Y; Ahmed W; He M; Xiang X; Tang R; Cui ZN
Eur J Med Chem; 2020 Dec; 207():112795. PubMed ID: 33002845
[TBL] [Abstract][Full Text] [Related]
10. Discovery of 2-(3,4-dialkoxyphenyl)-2-(substituted pyridazin-3-yl)acetonitriles as phosphodiesterase 4 inhibitors with anti-neuroinflammation potential based on three-dimensional quantitative structure-activity relationship study.
Huang C; Zhong QP; Tang L; Wang HT; Xu JP; Zhou ZZ
Chem Biol Drug Des; 2019 Apr; 93(4):484-502. PubMed ID: 30588755
[TBL] [Abstract][Full Text] [Related]
11. Powerful relaxation of phosphodiesterase type 4 inhibitor rolipram in the pig and human bladder neck.
Ribeiro ASF; Fernandes VS; Martínez-Sáenz A; Martínez P; Barahona MV; Orensanz LM; Blaha I; Serrano-Margüello D; Bustamante S; Carballido J; García-Sacristán A; Prieto D; Hernández M
J Sex Med; 2014 Apr; 11(4):930-941. PubMed ID: 24754330
[TBL] [Abstract][Full Text] [Related]
12. Discovery of triazines as potent, selective and orally active PDE4 inhibitors.
Gewald R; Grunwald C; Egerland U
Bioorg Med Chem Lett; 2013 Aug; 23(15):4308-14. PubMed ID: 23806553
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and biological evaluation of novel catecholopyrimidine based PDE4 inhibitor for the treatment of atopic dermatitis.
Purushothaman B; Arumugam P; Kulsi G; Song JM
Eur J Med Chem; 2018 Feb; 145():673-690. PubMed ID: 29353721
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and biological evaluation of novel tetrahydroisoquinoline derivatives as potential PDE4 inhibitors.
Song G; Zhao D; Hu D; Li Y; Jin H; Cui Z
Bioorg Med Chem Lett; 2015 Oct; 25(20):4610-4. PubMed ID: 26320621
[TBL] [Abstract][Full Text] [Related]
15. Discovery of potent, selective, bioavailable phosphodiesterase 2 (PDE2) inhibitors active in an osteoarthritis pain model, part I: transformation of selective pyrazolodiazepinone phosphodiesterase 4 (PDE4) inhibitors into selective PDE2 inhibitors.
Plummer MS; Cornicelli J; Roark H; Skalitzky DJ; Stankovic CJ; Bove S; Pandit J; Goodman A; Hicks J; Shahripour A; Beidler D; Lu XK; Sanchez B; Whitehead C; Sarver R; Braden T; Gowan R; Shen XQ; Welch K; Ogden A; Sadagopan N; Baum H; Miller H; Banotai C; Spessard C; Lightle S
Bioorg Med Chem Lett; 2013 Jun; 23(11):3438-42. PubMed ID: 23582272
[TBL] [Abstract][Full Text] [Related]
16. Elucidation of a structural basis for the inhibitor-driven, p62 (SQSTM1)-dependent intracellular redistribution of cAMP phosphodiesterase-4A4 (PDE4A4).
Day JP; Lindsay B; Riddell T; Jiang Z; Allcock RW; Abraham A; Sookup S; Christian F; Bogum J; Martin EK; Rae RL; Anthony D; Rosair GM; Houslay DM; Huston E; Baillie GS; Klussmann E; Houslay MD; Adams DR
J Med Chem; 2011 May; 54(9):3331-47. PubMed ID: 21456625
[TBL] [Abstract][Full Text] [Related]
17. Chemical informatics uncovers a new role for moexipril as a novel inhibitor of cAMP phosphodiesterase-4 (PDE4).
Cameron RT; Coleman RG; Day JP; Yalla KC; Houslay MD; Adams DR; Shoichet BK; Baillie GS
Biochem Pharmacol; 2013 May; 85(9):1297-305. PubMed ID: 23473803
[TBL] [Abstract][Full Text] [Related]
18. Repurposing human PDE4 inhibitors for neglected tropical diseases. Evaluation of analogs of the human PDE4 inhibitor GSK-256066 as inhibitors of PDEB1 of Trypanosoma brucei.
Ochiana SO; Bland ND; Settimo L; Campbell RK; Pollastri MP
Chem Biol Drug Des; 2015 May; 85(5):549-64. PubMed ID: 25283372
[TBL] [Abstract][Full Text] [Related]
19. Structure-Aided Identification and Optimization of Tetrahydro-isoquinolines as Novel PDE4 Inhibitors Leading to Discovery of an Effective Antipsoriasis Agent.
Zhang X; Dong G; Li H; Chen W; Li J; Feng C; Gu Z; Zhu F; Zhang R; Li M; Tang W; Liu H; Xu Y
J Med Chem; 2019 Jun; 62(11):5579-5593. PubMed ID: 31099559
[TBL] [Abstract][Full Text] [Related]
20. Phosphodiesterase 4 in macrophages: relationship between cAMP accumulation, suppression of cAMP hydrolysis and inhibition of [3H]R-(-)-rolipram binding by selective inhibitors.
Kelly JJ; Barnes PJ; Giembycz MA
Biochem J; 1996 Sep; 318 ( Pt 2)(Pt 2):425-36. PubMed ID: 8809029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
